- FDA Approves Biorphen (phenylephrine hydrochloride) Ready-to-Use Injection for Hypotension During Anesthesia
- FDA Approves Trikafta (elexacaftor/ivacaftor/tezacaftor) for Cystic Fibrosis Patients Ages 12 and Older Who Have at Least One F508del Mutation
- FDA Approves Trikafta (elexacaftor/ivacaftor/tezacaftor) for Cystic Fibrosis
- FDA Approves Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Cystic Fibrosis Patients Ages 12 and Older Who Have at Least One F508del Mutation
- Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
- FDA Approves Farxiga (dapagliflozin) to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes
- FDA Approves Amzeeq (minocycline) Topical Foam for the Treatment of Moderate to Severe Acne
- Alexion Receives FDA Approval for Ultomiris (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (AHUS)
- Nplate (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
- Genentech Announces FDA Approval of Xofluza (baloxavir marboxil) for People at High Risk of Developing Influenza-Related Complications
- FDA Approves Secuado (asenapine) Transdermal System for the Treatment of Adults with Schizophrenia
- FDA Approves Xarelto (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
- FDA Approves Reyvow (lasmiditan), the First Serotonin (5-HT) 1F Receptor Agonist for the Acute Treatment for Migraine
- FDA Approves Quzyttir (cetirizine) Injection for the Treatment of Acute Urticaria
- FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD)